Tracker Infusion Catheter
Target Therapeutics
FDA Clearance Information
The tracker infusion catheter was cleared through the FDA 510k pathway on October 1, 1986. It is manufactured by Target Therapeutics and classified as a Class 2 device under product code DQY.
What It Is
FDA-Cleared Indications
- Use as a percutaneous catheter for intravascular access and administration of fluids or therapeutic agents, consistent with the device labeling.
- Use under imaging guidance in vascular procedures when catheter-based delivery is clinically indicated.
Clinical Applications
- Catheter-based delivery of a therapeutic agent within a blood vessel.
- Percutaneous vascular access during diagnostic or interventional procedures.
- Selective catheterization of a target vessel when directed delivery is required.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The available record does not provide the catheter's French sizes, length options, lumen configuration, guidewire compatibility, or maximum injection pressure; these should be verified in the original instructions for use.
- Use requires appropriate vascular access, sterile technique, and imaging guidance. Catheter selection should match the target vessel, access route, and intended infusion.
- Potential complications of percutaneous intravascular catheterization include bleeding, hematoma, vascular injury, thrombosis, infection, embolization, and contrast-related reactions.
- MRI safety cannot be determined from the supplied FDA record. Check the current device labeling before MRI or use near an MRI system.
- Do not use when the catheter, infusion agent, access route, or planned procedure is contraindicated; review allergies, coagulation status, renal function when contrast is planned, and relevant vascular anatomy.
Procedures that use this device
Frequently Asked Questions
What are the clinical indications for tracker infusion catheter?
The device is indicated for use in venous stents and targeted drug delivery, particularly in vascular and oncological interventions.
What outcomes have been reported in clinical studies?
Studies have reported improved drug delivery accuracy and enhanced therapeutic outcomes, particularly in chemotherapy and vascular interventions.
What complications have been reported?
Safety data indicates potential complications such as limited mobility due to device placement and hematoma formation, though overall complication rates are low.